University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
May 12, 2026

Members attending the meeting: Bieniek, Kevin; Chatterjee, Bandana; Chen, Ching-Kang Jason; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Kautz, Tiffany; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin; Salamango, Daniel; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Melendez, Griselda; Barlett, Emily.

Absent members: Cerecero, Jennifer; Burgin, Tiffani; Chen, Chun-Liang; Gauduin, Marie Claire; Prewit, Egle.

1. **Panel Chair Announcement**
   The meeting was called to order at 11:00 a.m. by the IBC Chair, Dr. Yan Xiang.

2. **Confidentiality of Panel Proceedings and Conflict of Interest**
   The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

   Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. **Approval of minutes from the previous meeting**
   The Committee approved the minutes as written from the April 14, 2026, IBC meeting.
   Approved (19 voted to approve, 0 opposed, 0 abstained)

4. **Review of Approved Protocols-** The spreadsheet of approved protocols for FY2026 will be sent out for review in August 2026.

5. **Old Business –** None

6. **Educational Items –** None

7. **Occupational Medicine-** As of May 1, 2026, there were six cases of needlesticks, one case was by a UT staff member, and five cases were by UT students. There were five cases of bloodborne exposure: one involving a student and four involving UT staff members.

8. Other – None

9. Review of EHS Assistant-
Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on June 09, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021869
Principal Investigator: Sayre, Naomi; Neurosurgery
Title: LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response.
Review Type: Full Committee Review
Form Type: Renewal
Approved (19 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with lentivirus, lentiviral vectors (pLKO.1-puro, pLenti-C-GFP-CXCR4), hTau protein, and transfected human cell lines at BSL-2 containment. Work with knock-out mice strain (TNFR1) and transgenic mice strains (LRP1, ApoE314, Cre recombinase, GFP, YFP, td-tomato, Nestin cre, CXCR4) at ABSL-1 containment.

In vivo:
Work with lentiviral vectors (pLenti-C-GFP-CXCR4, pLenti-C-mGFP), Lentivirus, and hTau proteins in knockout and transgenic mice at ABSL-2 containment.
IACUC# 20230041AR, 20220078AR
Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

12. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021226
Principal Investigator: Griffith, Ann; Microbiology, Immunology & Molecular Genetics

Title: The role of Medullary Thymic Epithelial cell-derived growth factors in regulating Thymus growth and atrophy.
Review Type: Full Committee Review
Form Type: Renewal

Approved (19 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with influenza, vector (puC57), human blood, tissue, and body fluids at BSL-2 containment. Work with Complete Freund's Adjuvant at BSL-1 containment. Work with knock-out mice strains (Aire, IL7R, FoxN1, ApoE, MuMt) and transgenic mice strains (FoxN1, RFP(floxed), Rag2-GFP, Sirt1, TCRalpha/beta, FoxP3GFP, BDC2.5, ApoB, TAchR, LPO-Cre, LPP-CreERT2) at ABSL-1 containment.
Work with transgenic mouse strain Catalase at ABSL-2 containment.
IACUC# 15027X, 1900095X

In vivo:
Work with Complete Freund's Adjuvant in knockout and transgenic mice at ABSL-1 containment.
IACUC# IAMEND202500000414

Work with influenza at ABSL-2 containment.
IACUC# 15027X
Protocol does include the use of recombinant DNA.

This protocol was approved with minor corrections.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3
Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

13. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021802
Principal Investigator: Gaczynska, Maria; Molecular Medicine
Title: N/A
Review Type: Full Committee Review
Form Type: Renewal

Approved (19 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with Endothelial cells, human blood, human cell lines (PC3, MCF-7, LNCAP,

HeLa53, HEK293, DU145, Hs578Bst, Hs578T, MDA MB435, MDA MB468, MDA MB231, NIH3T3, RPMI8226, U937, THP-1, BPH-1, 22Rv1, C4-2B, PC#-RedFLuc-GFP, 143B, SK-N-SH), vectors (pGL3, pcDNA, pBR322, puc19, pBluescript, pDEST, pNLF1, pGEX, pET, pYES) at BSL-2 containment. Work with E. coli and yeast at BSL-1 containment.
Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

14. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021861
Principal Investigator: Zhao, Peng; Biochemistry & Structural Biology
Title: N/A
Review Type: Full Committee Review
Form Type: Renewal

Approved (19 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human cell lines (HEK293T, HepG2), vectors (pcDNA3, lentiviral vector, AAV vector), Lentivirus, AAV virus, and animal cell line 3T3LI at BSL-2 containment. Work with knock-out mouse strain (AMPKalph1/alpha2, Casp6, Ulk1) and transgenic mice (E06scFv) at ABSL-1 containment.
IACUC # 20200115
Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

15. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 0000021871
Principal Investigator: Chen, Lizhen; Barshop Institute

Title: The role of CELF2 and its genetic variants in Alzheimer's disease.
Review Type: Full Committee Review
Form Type: Renewal

Approved (19 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human stem cells at BSL-2 containment.
Work with AAV and AAV vector at BSL-1 containment.
Work with knock-out mouse strain (Celf2) and transgenic mice (CamKII) at ABSL-1 containment.
IACUC # 200082X, 200087R

In vivo:
Work with AAV in knock-out and transgenic at ABSL-2 containment.
IACUC# 200082R
Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Adjourn: The meeting adjourned at 11:55 A.M.

Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio

Dorothy Macias
Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam